American Journal of Kidney Diseases
Volume 54, Issue 2 , Pages 307-317 , August 2009

Oral Nicorandil to Reduce Cardiac Death After Coronary Revascularization in Hemodialysis Patients: A Randomized Trial

  • Masato Nishimura, MD, PhD

      Affiliations

    • Cardiovascular Division, Toujinkai Hospital, Kyoto, Japan
    • Corresponding Author InformationAddress correspondence to Masato Nishimura, MD, PhD, Cardiovascular Division, Toujinkai Hospital, 83-1, Iga, Momoyama-cho, Fushimi-ku, Kyoto 612-8026, Japan
    • ,
  • Toshiko Tokoro, MD, PhD

      Affiliations

    • Division of Nephrology, Toujinkai Hospital, Kyoto, Japan
    • ,
  • Masasya Nishida, MD

      Affiliations

    • Division of Urology, Toujinkai Hospital, Kyoto, Japan
    • ,
  • Tetsuya Hashimoto, MD

      Affiliations

    • Division of Urology, Toujinkai Hospital, Kyoto, Japan
    • ,
  • Hiroyuki Kobayashi, MD

      Affiliations

    • Division of Urology, Toujinkai Hospital, Kyoto, Japan
    • ,
  • Ryo Imai, MD, PhD

      Affiliations

    • Division of Orthopedics, Toujinkai Hospital, Kyoto, Japan
    • ,
  • Satoru Yamazaki, MD

      Affiliations

    • Toujinkai Clinic, Kyoto, Japan
    • ,
  • Koji Okino, MD, PhD

      Affiliations

    • Toujinkai Satellite Clinic, Kyoto, Japan
    • ,
  • Noriyuki Iwamoto, MD

      Affiliations

    • Division of Urology, Toujinkai Hospital, Kyoto, Japan
    • ,
  • Hakuo Takahashi, MD, PhD

      Affiliations

    • Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Osaka, Japan
    • ,
  • Toshihiko Ono, MD

      Affiliations

    • Division of Urology, Toujinkai Hospital, Kyoto, Japan

Received 24 November 2008 ,Accepted 31 March 2009.

References 

  1. Szczech LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int. 2001;60:292–299
  2. Le Feuvre C, Dambrin G, Helft G, et al. Clinical outcome following angioplasty in dialysis patients: A case-control study in the era of coronary stenting. Heart. 2001;85:556–560
  3. Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. Circulation. 2004;110:1890–1895
  4. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation. 2002;106:2207–2211
  5. Hemmelgarn BR, Ghali WA, Quan H, et al. Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis. 2001;37:64–72
  6. Ting HH, Tahirkheli NK, Berger PB, et al. Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. Am J Cardiol. 2001;87:630–633
  7. Nishimura M, Tokoro T, Nishida M, et al. Association of insulin resistance with de novo coronary stenosis after percutaneous coronary artery intervention in hemodialysis patients. Nephron Clin Pract. 2008;109:c9–c17
  8. Taira N, Satoh K, Yanagisawa T, Imai Y, Hiwatari M. Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75). Clin Exp Pharmacol Physiol. 1979;6:301–316
  9. Kukovetz WR, Holzmann S, Braida C, Pöch G. Dual mechanism of the relaxing effect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization. J Cardiovasc Pharmacol. 1991;17:627–633
  10. Taira N. Nicorandil is a hybrid between nitrates and potassium channel activators. J Cardiol. 1989;63:18J–24J
  11. Lee TM, Su SF, Chou TF, Lee YT, Tsai CH. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation. 2002;105:334–340
  12. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: The Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet. 2002;359:1269–1275
  13. Nishimura M, Tokoro T, Nishida M, et al. Clinical potential of nicorandil to inhibit major cardiac events in hemodialysis patients with suspected myocardial ischemia. Nephron Clin Pract. 2009;111:c212–c221
  14. Ishii H, Toriyama T, Aoyama T, et al. Efficacy of oral nicorandil in patients with end-stage renal disease: A retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther. 2007;29:1–13
  15. Nishimura M, Hashimoto T, Kobayashi H, et al. Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int. 2004;66:811–819
  16. Nishimura M, Tsukamoto K, Hasebe N, et al. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol. 2008;51:139–145
  17. Nishimura M, Murase M, Hashimoto T, et al. Insulin resistance and impaired myocardial fatty acid metabolism in dialysis patients with normal coronary arteries. Kidney Int. 2006;69:553–559
  18. Sahn DJ, DeMaria A, Kisso J, Weyman A. The Committee on M-mode Standardization of the American Society of Echocardiography: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083
  19. Demirovic J, Myerburg RJ. Epidemiology of sudden coronary death: An overview. Prog Cardiovasc Dis. 1994;37:39–48
  20. Amann K, Neusüss R, Ritz E, Irzyniec T, Wiest G, Mall G. Changes in vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens. 1995;8:409–417
  21. Barenbrock M, Spieker C, Laske V, et al. Studies of vessel wall properties in hemodialysis patients. Kidney Int. 1994;45:1397–1400
  22. Törnig J, Gross ML, Simonaviciene A, Mall G, Ritz E, Amann K. Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure. J Am Soc Nephrol. 1999;10:77–83
  23. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 1998;9:1018–1022
  24. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570–580
  25. Kotani J, Mintz GS, Pregowski J, et al. Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol. 2003;92:728–732
  26. Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002;23:1112–1117
  27. Hamburger WW, Priest WS, Bettman RB, Howard HC. Experimental coronary embolism. Am J Med Sci. 1926;171:168–184
  28. Agress CM, Rosenberg MJ, Jacobs HI, Binder MJ, Schneiderman A, Clark WG. Protracted shock in the closed-chest dog following coronary embolization with graded microspheres. Am J Physiol. 1952;170:536–549
  29. Marcus E, Katz LN, Pick R, Stamler J. The production of myocardial infarction: Chronic coronary insufficiency and chronic coronary heart disease in the dog. Acta Cardiol. 1958;13:536–549
  30. Jacoby JA, Taylor WJ, Smith GT, Gorlin R, Harken DE. A new therapeutic approach to acute coronary occlusion with microspheres. Am J Cardiol. 1962;9:60–73
  31. Bing RJ, Castellanos A, Gradel E, Lupton C, Siegel A. Experimental myocardial infarction: Circulatory biochemical and pathologic changes. Am Med Sci. 1956;232:533–554
  32. Akai K, Wang Y, Sato K, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: Its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 1995;26:541–547
  33. Kasama S, Toyama T, Hatori T, et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. Am Heart J. 2005;150:477
  34. Miyazaki T, Moritani K, Miyoshi S, et al. Nicorandil augments regional ischemia-induced monophasic action potential shortening and potassium accumulation without serious proarrhythmia. J Cardiovasc Pharmacol. 1995;26:949–956
  35. Sakamoto T, Kaikita K, Miyamoto S, et al. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease. Circ J. 2004;68:232–235
  36. Nagata K, Obata K, Odashima M, et al. Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation of mitochondrial ATP-sensitive potassium channels and a nitrate-like effect. J Mol Cell Cardiol. 2003;35:1505–1512
  37. Furukawa K, Itoh T, Kajiwara M, et al. Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guinea-pig coronary artery. J Pharmacol Exp Ther. 1981;218:248–259
  38. Kawano K, Yamaguchi M. Absorption and filtration of nicorandil with various types of dialytic membranes. Igaku To Yakugaku. 1999;41:1137–1141
  39. Frydman AM. Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol. 1992;20(suppl 3):S34–S44
  40. Simpson D, Wellington K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs. 2004;64:1941–1955
  41. Zhu W-L, Shan Y-D, Guo J-X, et al. Double-blind, multicenter, active controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J. 2007;71:826–833
  42. Molinaro M, Villa G, Regazzi MB, et al. Pharmacokinetics of nicorandil in patients with normal and impaired renal function. Eur J Clin Pharmacol. 1992;42:203–207

 Originally published online as doi: 10.1053/j.ajkd.2009.03.025 on June 18, 2009.

 Trial registration: www.ClinicalTrials.gov; study number: NCT00848562.

PII: S0272-6386(09)00723-9

doi: 10.1053/j.ajkd.2009.03.025

American Journal of Kidney Diseases
Volume 54, Issue 2 , Pages 307-317 , August 2009

Article Tools

* Image Usage & Resolution